MRSN vs REGN · rev $40.5M vs P/E 14, rev $4.29B
Mersana Therapeutics Inc (MRSN) versus Regeneron Pharmaceuticals Inc (REGN) — a side-by-side from cached financials, not a winner call.
Mersana Therapeutics Inc (MRSN) is a biotechnology company listed on NASDAQ.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Latest reported MRSN revenue for 2024-12-31 was $40.5M. Net income was -$69.2M. Revenue was up 9.9% from 2023-12-31 to 2024-12-31. MRSN currently screens at market cap $145.4M.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
MRSN currently screens at market cap $145.4M. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Not investment advice. Open the MRSN and REGN stock pages for the full models.
Not investment advice.